Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

Liontos, Michalis; Terpos, Evangelos; Markellos, Christos; Zagouri, Flora; Briasoulis, Alexandros; Katsiana, Ioanna; Skafida, Efthymia; Fiste, Oraianthi; Kunadis, Elena; Andrikopoulou, Angeliki; Kaparelou, Maria; Koutsoukos, Konstantinos; Gavriatopoulou, Maria; Kastritis, Efstathios; Trougakos, Ioannis P.; Dimopoulos, Meletios-Athanasios

Objective: Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic therapy. Methods: In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volunteers in order to study the kinetics of anti-SARS-CoV-2 antibodies (NAbs) after COVID-19 vaccination. Baseline demographics, co-morbidities, and NAb levels were compared between the two groups. Results: The results of the cohort of 36 patients receiving PARP inhibitors are presented here. Despite no new safety issues being noticed, their levels of SARS-CoV-2 neutralizing antibodies were significantly lower in comparison to matched healthy volunteers up to day 30 after the second dose. Conclusions: These results suggest that maintaining precautions against COVID-19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.